Healthcare industry

The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

Scientists from the Tübingen Competence Center for Machine Learning and physicians from the University Hospital of Tübingen have developed an app that uses anonymous health data to contribute to a better understanding of the novel coronavirus.

Prime Vector Technologies GmbH - 09/04/2020

A modular brick system for developing a COVID-19 vaccine

Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

Scientists from Heidelberg and Mannheim launch research and development task force

Novel coronavirus outbreak - a status report on recent developments - 04/03/2020

Waiting for a SARS-CoV-2 vaccine

Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

Asthma is the most common chronic disease in children. One in ten children suffer from bronchial restriction and produce elevated amounts of lung mucus. On 02.05.2017 is "World Asthma Day" – the BIOPRO provides information about this topic.

Article - 15/09/2014

Gene therapies for pulmonary disease are close to final development

Gene therapy currently offers the only chance of curing genetic diseases such as cystic fibrosis and beta thalassaemia. Gene therapy is the replacement or correction of a mutated gene with DNA that encodes a functional gene. Intensive research has been going on in this field for many years however only a handful gene therapies are available at this point in time. Dr. Michael Kormann junior professor at the Childrens Hospital at the University of…

Article - 30/06/2014

The German National Cohort: collecting data for a healthier future

A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early…

Article - 14/01/2013

Boehringer takes a deep breath: a look into the company’s respiratory R&D pipeline

At its 3rd International Research & Development (R&D) press conference, Boehringer Ingelheim gave journalists insights into its R&D pipeline. Around 200 scientists at the company’s site in Biberach are investigating new treatment options for patients with COPD (chronic obstructive pulmonary disease), asthma, idiopathic lung fibrosis, lung cancer and other respiratory diseases. In addition, the researchers are also focusing on the…

Press release - 24/08/2011

KIT Researcher Win the Mimics Innovation Awards 2011 in the Category “Innovations in Computer Aided Engineering”

The contribution “A Preprocessing Approach for Innovative Patient-Specific Intranasal Flow Simulations” of Krause (EMCL), Gengenbach (EMCL), Mayer (SCC), Zimny (EMCL) and Heuveline (Head of EMCL) has won the Mimics Innovation Awards 2011 in the category 2 “Innovations in computer aided engineering” which is associated with a prize of 5,000 Euro.

Article - 18/03/2011

Allergen research – present and future

An allergy is a hypersensitivity disorder of the immune system. It is an exaggerated immune reaction to external stimuli such as pollen and is associated with symptoms that range in degree from uncomfortable (hay fever, asthma) to life-threatening (anaphylactic shock). Dr. Thomas Bethke, Medical Director of Nycomed Germany, explains in the following interview how a drug manufacturer approaches the research and development of anti-allergy…

Press release - 11/09/2010

What’s new from bacteria’s box of tricks?

Cell biologists at the University of Konstanz have discovered how specialised bacteria colonise human mucosal surfaces. Prof. Dr. Christof Haucks team is mainly interested in a mechanism known as exfoliation i.e. the shedding of epithelial cells which certain bacteria suppress in order to be able to effectively colonise mucosal surfaces.

Press release - 09/09/2010

Global market launch of Daxas® kicks off in Germany

Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas® (Roflumilast) in Oranienburg today, making Germany the first country to market the medicine. Daxas® is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.

With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through to market entry. Quality Certification for its diagnostic product development represents an additional milestone in Curetis' commercial strategy. At the same time, Curetis has added internationally recognized expertise in…

Press release - 29/04/2010

Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada

Nycomed and Merck Co. Inc. based in Whitehouse Station New Jersey and known as MSD outside the USA and Canada announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas roflumilast an investigational once-daily tablet for patients with chronic obstructive pulmonary disease COPD.

Article - 18/03/2010

Boehringer Ingelheim researchers to focus on inflammation

Boehringer Ingelheim is hoping to find ways to use anti-inflammatory mechanisms of action to improve the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Clinical studies will show what kind of improvements patients can expect from the substances, which are currently at different stages of development. Drugs to widen the bronchia, marketed by Boehringer Ingelheim, will in the medium term become…

Dossier - 22/02/2010

Respiratory disease - congestion in the respiratory system

Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…

Article - 22/02/2010

Immune system discovers mould fungi through surface structures

Mould fungus spores which are found in air aerosols are constantly being taken up in the air we inhale. As a rule this poses no danger to healthy people. However depending on the quantity of spores inhaled and the duration of exposure mould fungi could possibly lead or contribute to lung diseases and allergies. Dr. Mardas Daneshian and his team at the University of Constance are focusing on the immunostimulatory capacity of fungal spores. The…

Eight projects in the preclinical and first clinical stage will be transferred to 4SC. Nycomed decided not to further invest in oncology RD activities. 4SC develops drug candidates for inflammatory diseases cancer and infectious diseases.

Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India. Based on this agreement, Nycomed plans to transfer the current chemical production from the sites in Linz (Austria) and Singen (Germany) to the new joint venture within the next three to four…